Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp.

TNXP

0.00
  • Tonix Pharmaceuticals highlighted the commercial rollout of fibromyalgia drug TONMYA, launched Nov. 17, 2025; FDA clearance cited for Aug. 2025.
  • Reported TONMYA net sales of USD 3.7 million in 1Q26; USD 5.1 million from Nov. 17, 2025 to Mar. 31, 2026.
  • Commercial metrics showed more than 2,600 unique prescribers from Nov. 17, 2025 to Apr. 17, 2026; about 11,016 prescriptions through May 1, 2026.
  • Cash and cash equivalents totaled about USD 185.5 million as of March 31, 2026; no debt; runway expected into early Q2 2027.
  • Pipeline focus included TNX-4800 Lyme disease prevention study planned for 1H27; TNX-1500 transplant rejection Phase 2 planned mid-2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.